{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Stocks and Bonds", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Bausch & Lomb Incorporated", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Philidor Rx Services LLC", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "6", "is_major": "N"}, {"value": "Schiller, Howard B", "name": "persons", "rank": "7", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/14/business/valeant-woes-rising-backs-away-from-boldness-to-calm-investors.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/13/business/14valeant1/13valeant1-thumbWide.jpg", "legacy": {"wide": "images/2016/03/13/business/14valeant1/13valeant1-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/13/business/14valeant1/13valeant1-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/13/business/14valeant1/13valeant1-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/03/13/business/14valeant1/13valeant1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/13/business/14valeant1/13valeant1-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "928", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The drug maker, which made big profits by raising the price of old drugs, is now talking about investing in research and paying down debt as its stock price slumps.", "pub_date": "2016-03-14T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Woes Rising, Valeant Puts a Staid Spin on Its Plans", "main": "Valeant, Woes Rising, Backs Away From Boldness to Calm Investors"}, "print_page": "1", "snippet": "The drug maker, which made big profits by raising the price of old drugs, is now talking about investing in research and paying down debt as its stock price slumps.", "_id": "56e59b0338f0d82d8fe39ecd", "slideshow_credits": null, "abstract": "Valeant is expected to announce fourth-quarter earnings and set financial guidance for coming year; executives have been struggling to convince investors that company is on correct path and have emphasized that company is investing in research and development and addressing its $30 billion in debt."}